IDEA Pharma has appointed Mark Forbes Irving as managing director. With over 20 years’ industry experience, Mark joins the company from Quintiles, where he was director of health engagement and communications. Prior to that, he worked in both industry marketing and consultancy sectors where he had managing director level experience leading multiple firms.
Takeda UK has made two new appointments – Simon Meadowcroft as medical director and Pauline Bromley as human resources director. Simon has held senior positions at Novartis and GSK, developing and driving the strategy for key assets within their oncology portfolios. Pauline has over 15 years’ experience working with small and large pharmaceutical organisations and joins from LEO Pharma.
Drug discovery company Crescendo Biologics Limited has appointed Dr Kevin Johnson as non-executive chairman of the board of directors. Kevin brings 27 years of antibody development experience, notably as ex-CTO of Cambridge Antibody Technology and ex-CEO of Pangenetics (acquired by Abbott in 2009). Since 2003 he has been on the Life Sciences team of Index Ventures, focusing on drug development companies.
Wyndham Clark has joined the board of DJM PAN Unlimited – the new combination of DJM and PAN – as client services director. Previously Wyndham was client services director for Publicis Life Brands Resolute where he had direct account responsibility for clients including AstraZeneca, Boehringer Ingelheim, and Sanofi. Before that Wyndham worked as a director at both Story Worldwide and Hive Health.
PlaqueTec, a Cambridge-based company developing biomarker-based approaches to understanding coronary artery disease (CAD), the leading cause of death worldwide, has appointed Dr Nick West as chief medical officer. Nick is a consultant interventional cardiologist at Papworth Hospital, Cambridge, and has also acted as an expert advisor to NICE, peer-reviews for journals and is a faculty member at national and international Cardiology meetings. Nick has consulted with PlaqueTec for a number of years as medical advisor, and was principal investigator for both the company’s recent clinical study and the first-in-man study that preceded it.
UK-based drug discovery services provider Peakdale Molecular (part of the Concept Life Sciences Group) has named Gordon Woodrow as head of sales and marketing. Gordon joins Peakdale with over 25 years of commercial experience having held a number of senior positions in companies offering scientific services to the pharmaceutical and biotech industries. Most recently he was responsible for business development and strategic alliances at Proteros Biostructures.
Tiziana Life Sciences has named Willy Simon as a non-executive director. Willy is a banker and worked at Kredietbank NV and Citibank London before serving as an executive member of the board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment Management from 1999 to 2002.
Professor Michael Linden has joined Pfizer to head its new genetics medicines research centre in London. Michael has spent over 20 years researching the potential of certain viruses to transport genetic medicines into the body. He has been supporting Pfizer in this area for 11 months on a secondment from King’s College London, where he worked as a professor of virology, but is now joining the company as a full-time colleague.
Professor Alan Boyd has been elected as the next president of the The Faculty of Pharmaceutical Medicine of the UK’s Royal College of Physicians. Alan has been vice president of the Faculty from 2012-2015 and was involved in the development of Good Pharmaceutical Medical Practice. He has also been the chair of the Education Committee and the Specialist Advisory Committee in Pharmaceutical Medicine for the faculty.
Ablynx has appointed Robert Zeldin as chief medical officer. Robert will lead the company's global clinical development, regulatory and medical affairs activities. He has held senior level clinical development positions at top tier pharmaceutical companies, including Merck & Co and Novartis. In his previous roles, Robert headed teams in immunology, respiratory, dermatology and cardiovascular disease where he was responsible for clinical development through to commercialisation and life cycle management.
PureTech has named Harry Leider as a senior advisor to the company, and appointed Dr Joe Bolen as entrepreneur-in-residence (EIR). Harry is currently chief medical officer and group vice president at Walgreens, and will be advising PureTech on commercialisation and reimbursement strategies for its advanced programmes. As an EIR, Joe will work with PureTech’s company creation team to identify and pursue promising new medicines. He most recently oversaw all aspects of research and development for Moderna Therapeutics as president and chief scientific officer.
Daniel Reynolds has joined NHS Providers as director of communications. Daniel is currently director of communications at the Nuffield Trust, and prior to that was deputy director of communications at the King’s Fund.
Greenphire, a provider of payment technology for the clinical trials industry, has appointed David Horsley as senior director of European business development. David will be responsible for enhancing and extending Greenphire's continued presence in Europe and identifying new sources of growth for the company. He has spent over 20 years in the pharmaceutical industry, including 15 years working in the clinical trials technology sector. Most recently he worked as senior director for the Perceptive Partner Program in PAREXEL’s Perceptive Informatics division.
Jackie Hunter has been named as the new CEO for Stratified Medical, a London tech-start up that is using artificial intelligence in pharmaceutical research. Previously Jackie was the chief executive of the Biotechnology and Biological Sciences Research Council (BBSRC), and prior to that was senior vice president in charge of neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline.
Auspherix, an early stage anti-infectives company, has announced the appointment of Dr Neil Miller as its chief scientific officer. Prior to joining Auspherix, Neil has spent two decades in the pharmaceutical industry at GlaxoSmithKline (GSK), most recently as senior director and head of chemistry, DMPK and external discovery in Singapore.
Liberation Unlimited has promoted Edward Mullin to account executive. Edward joined Liberation in 2014 and has since played an integral role across several accounts. Edward will continue to work on medical education and PR campaigns across a range of clinical areas such as respiratory, oncology and hypothyroidism.
Alzheimer’s Research UK has appointed three chief scientific officers to drive its £30 million Drug Discovery Alliance – Dr John Skidmore, Dr John Davis and Professor Paul Whiting. Skidmore, who will head up the Cambridge Drug Discovery Institute, is a medicinal chemist, with a wealth of expertise working in the neurodegeneration and pain disease areas at GSK. Davis, the new CSO of the Oxford Drug Discovery Institute, has 20 years of drug development expertise, from target to Phase IIa, and has helped steer a dozen drug candidates into clinical development. Whiting, who will lead the UCL Drug Discovery Institute, has built his career through over 20 years of pharmaceutical neuroscience drug discovery, and has published extensively in the field.
OBN, the membership organisation supporting the UK’s emerging life sciences companies, has appointed Dr John Harris as CEO. Currently John is delivering business and export advice to UK trade and industry clients, assisting Life Science companies on growth strategies both domestically and abroad. His most recent appointment was managing partner of Qube Associates, a specialist consultancy focusing on science-based SME’s.
Acacia Pharma has announced that Ian Kent will retire as non-executive chairman and will be succeeded by Dr Patrick Vink. Patrick most recently served as chief operating officer of Cubist Pharmaceuticals, joining there from senior roles at Mylan, including having global responsibility for the group’s hospital business. Previously he held several leadership positions with Novartis Sandoz, Sanofi and Biogen, principally in global commercial roles. He is also a non-executive director of Inhibikase and Micreos BV.
Peter Wyman has been appointed as the new chair of the Care Quality Commission (CQC) for four years. Peter is currently chairman of Yeovil District Hospital NHS Foundation Trust, but will be standing down from this position before taking up post as CQC Chair. He is also a board member and Chair of the Audit Committee at Companies House, and previously served as chairman of the Somerset Community Foundation, president of the Institute of Chartered Accountants in England & Wales, and senior partner at PricewaterhouseCoopers LLP.
Tony Gardiner has joined Avacta Group, a developer of biotherapeutics and research reagents, as chief financial officer. Tony joins Avacta from AHR, an international architecture and building consultancy practice, where he has held the role of finance director since 2011. Between 2007 and 2011, he was the CFO of AIM listed Fusion IP, an IP commercialisation company.
Jamie Hewitt has joined Portland Health as an account director. Jamie joins Portland from the National Rheumatoid Arthritis Society, where he was head of government affairs and led the charity’s policy and public affairs functions. During his time at the charity, he ran UK campaigns to increase access to medicines, raise disease awareness and influence legislation on health, social care and welfare reform.